Loading provider…
Loading provider…
Internal Medicine Physician in New York, NY
NPI: 1114030707Primary Employer
Memorial Neurology Group
mskcc.org
HQ Phone
Get M.D. Ingo's Phone Numberphone_androidMobile
Get M.D. Ingo's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1997 - 2027
NY State Medical License
2008 - 2027
NH State Medical License
2024 - 2026
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
1999 - 2004
Chief Residency • Internal Medicine
1998 - 1999
Residency • Internal Medicine
1995 - 1998
Technical University Munich Faculty of Medicine
Medical School
Until 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 33 | 127 |
Authors: Ahmet Dogan
Journal: Clin Cancer Res
Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET.
Authors: Maya Graham, Neeta Pandit-Taskar, Jason Lewis
Journal: Clin Cancer Res
Publication Date: 2021-01-25
Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Authors: Anna Piotrowski, Jian Campian, Jaishri Blakeley, Carlos Romo, Fausto Rodriguez, Tejus Bale
Journal: Neuro Oncol
Lead Sponsor: Patrick Y. Wen, MD
Collaborators: University of California, San Francisco, University of California, Los Angeles, Novartis Pharmaceuticals, Massachusetts General Hospital, Brigham and Women's Hospital, University of Utah, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center
Intervention / Treatment: PROCEDURE: Surgery, DRUG: BKM120
Lead Sponsor: Andrew B Lassman, MD
Collaborators: Genentech, Inc., OSI Pharmaceuticals
Intervention / Treatment: DRUG: erlotinib, PROCEDURE: Cytoreductive Surgery